Search results
Results From The WOW.Com Content Network
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical Asia , and Vaxxinity, Inc. [2] It is a peptide vaccine. [3] [4] It is composed of SARS-CoV-2 S1-RBD protein and synthetic peptides representing T cell (Th and CTL) epitopes on the nucleocapsid, spike and membrane proteins. The multitope composition is differentiated from ...
During the COVID-19 pandemic, anti-vaccination and anti-abortion activists believed that MRC-5 was an ingredient of the Oxford–AstraZeneca COVID-19 vaccine, citing a study from the University of Bristol. David Matthews, a co-author for this study, clarified that MRC-5 was solely used for testing purposes to determine "how the Oxford vaccine ...
N1-Methylpseudouridine is the methylated derivative of pseudouridine.It is used in in vitro transcription and for the production of RNA vaccines. [3] [4] In vertebrates, it stimulates significantly less activation of the innate immune response compared to uridine, [5] while the translation is stronger.
Studies have not observed a correlation between COVID vaccination and fertility. [423] [424] A UK study found COVID vaccination is safe for pregnant women and is associated with a 15% decrease in the odds of stillbirth. Vaccination is recommended for pregnant women because pregnancy increases the risk of severe COVID.
The preparation of ALC-0315 was first described in a patent application to lipid nanoparticles by Acuitas Therapeutics in 2017. [6]: 137 The final step is a reductive amination reaction in which 4-aminobutanol is condensed with a lipid aldehyde, using sodium triacetoxyborohydride as the reducing agent to convert the intermediate imines to the amine of the product.
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [ 2 ] [ 3 ] For its development, Arcturus collaborated with Vinbiocare , a Vietnamese company, for support with clinical trials and manufacturing.
SM-102 is a synthetic amino lipid which is used in combination with other lipids to form lipid nanoparticles. [1] These are used for the delivery of mRNA-based vaccines, [2] [3] [4] and in particular SM-102 forms part of the drug delivery system for the Moderna COVID-19 vaccine.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...